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Background Skin and soft tissue infections (SSTI) include, but are not limited to, paronychia, cellulitis,
erysipelas, folliculitis, impetigo, and abscess. To provide optimal treatment, clinicians must determine the location
and severity of infection, then consider pathogens specific to the particular SSTI as well as local antibiotic
resistance patterns. If antibiotics are indicated, they should be appropriately narrow and given for the minimal
necessary duration to minimize adverse effects including antibiotic resistance. In 2014, the Infectious Diseases
Society of America (IDSA) provided guidelines on the diagnosis and management of SSTI, recommending that
cellulitis be treated with a 5-day course of antibiotics. These guidelines also recommend that most other pediatric
SSTIs can be treated with a 5-7-day course of antibiotics. This CM Clinical Practice Guideline (CPG) serves as a
resource and decision support tool for clinicians, encouraging the use of evidence-based SSTI treatment.
Definition Skin and soft tissue infections (SSTIs) are clinical entities of variable presentation, etiology, and
severity that involve microbial invasion of the layers of the skin and underlying soft tissues (Ki et al., 2008).
Objective of Clinical Practice Guideline
•
Standardized treatment and appropriate antibiotic selection and duration
Target
•
•
•
•
•

Users
Primary Care Clinicians
Urgent Care
Emergency Medicine
Hospital Medicine
Infectious Disease

Target Population
Guideline Inclusion Criteria
Patients >60 days with suspected skin and soft tissue infection
Guideline Exclusion Criteria
•
Less than 60 days of age
•
Suspected sepsis
•
Animal or human bites
•
Surgical site infections
•
Suspected toxin-mediated reaction
•
Immunocompromised, including steroid use >14 days
•
Growth of multi-drug resistant organism in the past
•
Deeper infections (Myositis, Fasciitis)
•
Necrotizing infections
•
SSTI infection of face, tooth, eye, perineum, operative sites
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The Infectious Diseases Society of America guideline provided guidance to the SSTI CPG committee (Stevens et al.,
2014). See Table 1 for AGREE II.
Table 1.
AGREE IIa Summary for the Guideline Stevens et al. (2014)
Domain

Percent Agreement

Percent Justification

The aim of the guideline, the clinical
questions posed and target
populations were identified.
The guideline did not include
appropriate stakeholders (such as
Stakeholder involvement
58%
patients, nurses, parents,
pharmacists) nor the viewpoints of the
intended user.
The process used to gather and
synthesize the evidence, the methods
Rigor of development
81%
to formulate the recommendations
and to update the guidelines were
explicitly stated.
The guideline recommendations are
clear, unambiguous, and easily
Clarity and presentation
100%
identified; in addition, different
management options are presented.
The guideline did not address
implementation barriers and
Applicability
52%
facilitators, utilization strategies, or
resource costs associated
implementation.
The recommendations were not biased
Editorial independence
100%
with competing interests.
IDSA is used for diagnosis, evaluation,
Committee’s recommendation
and treatment recommendations. An
for guideline use
additional question was posed by the
Yes with modifications
CPG committee.
Note: Four EBP Scholars completed the AGREE II (Brouwers et al., 2010) on this guideline.
Scope and purpose

99%

Additional Question Posed by the CPG Committee (Appendix A)
1. In pediatric patients with suspected Skin and Soft Tissue Infection (SSTI), should antibiotics be prescribed
after the abscess is drained versus no antibiotics for the outcomes of cured at follow-up and rate of
recurrence?
Question Recommendation A conditional recommendation is made for the use of antibiotics for abscesses, based
on the GRADE Evidence to Decision instrument the Summary of Findings Table. The overall certainty in the
evidence is low to very low. In pediatric patients, the use of antibiotics following incision and drainage was
favorable for cure rate versus placebo. There is little evidence for or against antibiotics following incision and
drainage for abscesses.
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Practice Recommendations
Please refer to The Infectious Diseases Society of America Clinical Practice Guideline for full diagnosis, evaluation, and
treatment recommendations (Stevens et al., 2014).
Children’s Mercy Practice Recommendations and Reasoning
Children’s Mercy adopted the majority of the practice recommendations made by the IDSA Clinical Practice Guideline.
Deviations include:
The IDSA (Stevens et al., 2014) states “the addition of systemic antibiotics to incision and drainage of
cutaneous abscesses does not improve cure rates, even in those due to MRSA, but did have a modest effect
on the time to recurrence of other abscesses. However, systemic antibiotics should be given to patients with
severely impaired host defenses or signs or symptoms of systemic infection. In addition, multiple abscesses,
extremes of age, and lack of response to incision and drainage alone are additional settings in which systemic
antimicrobial therapy should be considered (Stevens et al. 2014, pg. e22).” Based on a current review of
literature, Children’s Mercy makes a conditional recommendation for the use of antibiotics for abscesses after
incision and drainage. The overall certainty in the evidence is low to very low. In pediatric patients, the use of
antibiotics following incision and drainage was favorable for cure rate versus placebo. There is little evidence
for or against antibiotics following incision and drainage for abscesses <2cm. (Supporting Evidence)
Outcome Measures
•
Increase percentage of patients receiving 5-7 days of antibiotics by 20%
Process Measures
•
Use of updated prescription folder within the electronic medical record
Review of CPG
Balance Measures
•
Return within 14 days with same diagnosis
Other
•
•
•

Potential
Reducing
Reducing
Reducing

Outcomes
risk of side effects or adverse events from medication
risk of antimicrobial resistance
healthcare cost (small)

Potential Organizational Barriers
•
Provider resistance to practice change
•
Provider concern for treatment failure with shorter antibiotic course
Order Sets(s) (Appendix B)
Guideline Preparation
This guideline was prepared by the Evidence Based Practice (EBP) Department in collaboration with content experts at
Children’s Mercy Kansas City. The development of this guideline supports the Service and Performance Excellence
initiative to promote care standardization that builds a culture of quality and safety that is evidenced by measured
outcomes. If a conflict of interest is identified the conflict will be disclosed next to the Committee member’s name.
Implementation & Follow-up
•
Once approved, the guideline was presented to appropriate care teams and implemented
•
Care measurements will be assessed and shared with appropriate care teams to determine if changes need to
occur
•
Creation of an algorithm to provide evidence-based and consistent care throughout CM
•
Creation of a standardized order set (Power Plan) consistent with the algorithm to provide additional decision
support and decrease the risk of ordering error
•
Education of providers in Urgent Care, Emergency Medicine, and Pediatric Hospital Medicine
•
This guideline is scheduled for revision on May 2025
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Disclaimer
When evidence is lacking or inconclusive, options in care are provided in the guideline and the order sets that
accompany the guideline.
These guidelines do not establish a standard of care to be followed in every case. It is recognized that each case is
different, and those individuals involved in providing health care are expected to use their judgment in determining
what is in the best interests of the patient based on the circumstances existing at the time.
It is impossible to anticipate all possible situations that may exist and to prepare guidelines for each. Accordingly,
these guidelines should guide care with the understanding that departures from them may be require
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Specific Care Question: In pediatric patients with suspected Skin and Soft Tissue Infection (SSTI), should antibiotics be prescribed after the abscess is
drained versus no antibiotics for the outcomes of cured at follow-up and rate of recurrence?
Recommendations from the Skin and Soft Tissue Infection CPG Team A conditional recommendation is made for the use of antibiotics for abscesses,
based on the GRADE Evidence to Decision instrument the Summary of Findings Table. The overall certainty in the evidence is low to very low. In pediatric
patients, the use of antibiotics following incision and drainage was favorable for cure rate versus placebo. There is little evidence for or against
antibiotics following incision and drainage for abscesses <2cm. (see Summary by Outcome for substantiation of recommendations).
The SSTI CPG Subcommittee discussed additional considerations using the GRADE Evidence to Decision instrument a found in the appendix to recommend
antibiotic therapy for abscess following incision and drainage at Children’s Mercy based on feasibility, value, and compliance for all stakeholders.
Literature Summary
Background
Skin and soft tissue infection is a common presentation in pediatric emergency departments and ambulatory settings, of which almost half are abscesses
(Gottlieb & Peksa, 2018; Taira et al., 2009). Standard clinical treatment for abscesses includes incision and drainage, but the utility of antibiotics for simple
abscesses remains unclear (Singer & Talan, 2014). The Infectious Diseases Society of America recommends that incision and drainage is likely adequate for
simple abscess (Stevens et al., 2014). A recent meta-analysis (Gottlieb & Peksa, 2018) of adults and pediatric patients found that systemic antibiotics for
abscesses after incision and drainage increased clinical cure rates. This contrasts with a previous meta-analysis (Fahimi et al., 2015) of adults and pediatric
patients that found no improvement in clinical cure rate. This review will summarize identified literature of pediatric patients to answer the specific care
question on the topic.
Study characteristics. The search for suitable studies was completed on August 31, 2021. A. Nedved, MD and E. Scott, DO reviewed the 147 titles and/or
abstracts found in the search and identifiedb one guideline and six single studies believed to answer the question. After an in-depth review of the guidelined
and the single studiesc, four answered the question(s). Two systematic reviews (SR) (Fahimi et al., 2015; Gottlieb et al., 2019) were identified in the
search. Both SRs included both adults and pediatric patients. Only the pediatric studies from the SRs were included in the current review.
Summary by Outcome
Cure Rate 7-10 days for Children, Trimethoprim / Sulfamethoxazole (TMP-SMX) versus Placebo
Two studies (Daum et al., 2017; Duong et al., 2010) measured cure rate at 7-10 days, (n = 329). For the outcome of cure rate at 7—10 days, the OR =
1.97, 95% CI [1.04, 3.73], p = .04, indicated the intervention of TMP-SMX was favorable to the comparator of placebo (see Figure 3 & Table 2). The use of
TMP-SMX would result in a cure rate of 6 to 133 more patients per 1000.
Certainty Of The Evidence For Cure Rate at 7-10 days for Children. The certainty of the body of evidence was low. The body of evidence was
assessed to have no serious inconsistency, no serious indirectness, but was assessed to have serious risk of bias and serious imprecision. Risk of bias
was serious as Duong et al. (2010) did not reach power and medication compliance was only 66%. Imprecision was serious due to the low number of
events and participants (n = 329).

* These guidelines do not establish a standard of care to be followed in every case. It is recognized that each case is different, and those individuals involved
in providing health care are expected to use their judgment in determining what is in the best interests of the patient based on the circumstances existing at
the time. It is impossible to anticipate all possible situations that may exist and to prepare guidelines for each. Accordingly, these guidelines should guide care
with the understanding that departures from them may be required at times.
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Cure Rate 7-14 days for Children and Adults, TMP-SMX versus Placebo
Three studies (Daum et al., 2017; Duong et al., 2010; Talan et al., 2016) measured cure rate at 7-14 days, (n = 1576). For the outcome of cure rate at 7—
14 days, the OR = 1.55, 95% CI [1.22, 1.97], p = .0005, indicated the intervention of TMP-SMX was favorable to the comparator of placebo (see Figure 3
& Table 2). The use of TMP-SMX would result in a cure rate of 34 to 105 more patients per 1000.
Certainty Of The Evidence For Cure Rate at 7-14 days for Children and Adults. The certainty of the body of evidence was low. The body of
evidence was assessed to have no serious inconsistency and no serious imprecision, but was assessed to have serious risk of bias and serious
indirectness. Risk of bias was serious due to potential selection bias (Talan et al., 2016). This study made up 86% of the final weight of the metaanalysis results. Indirectness was serious due to Talan et al. (2016) included both adults and children.
Recurrence at 3 months for Children, TMP-SMX versus Placebo for Children
One studies (Duong et al., 2010) measured recurrence at 3 months, (n = 98). For the outcome of recurrence at 3 months, the OR = 0.97, 95% CI [0.40,
2.34], p = .95, indicated the intervention of TMP-SMX was no different to the comparator of placebo (see Figure 5 & Table 2).
Certainty Of The Evidence For Cure Rate at 7-10 days for Children. The certainty of the body of evidence was. The body of evidence was
assessed to have no serious inconsistency, no serious indirectness, but was assessed to have serious risk of bias and serious imprecision. Risk of bias
was serious due to Duong et al. (2010) not recruit enough study participants to detect significance and the medication compliance of the subjects was
only 66%. Imprecision was serious due to the low number of events and participants (n = 98).
Adverse Events for Children, TMP-SMX versus Placebo
Two studies (Daum et al., 2017; Duong et al., 2010) measured adverse events, (n = 672). For the outcome of adverse events, the OR = 0.73, 95% CI
[0.47, 1.15], p = .18, indicated the intervention of TMP-SMX was no different to the comparator of placebo (see Figure 4 & Table 2).
Certainty Of The Evidence For Adverse Events for Children. The certainty of the body of evidence was. The body of evidence was assessed to
have no serious inconsistency, no serious indirectness, but was assessed to have serious risk of bias and serious imprecision. Risk of bias was serious
due to Duong et al. (2010) not recruit enough study participants to detect significance and the medication compliance of the subjects was only 66%.
Imprecision was serious due to the low number of events (n = 186).
Adverse Events for Children and Adults, TMP-SMX versus Placebo
Three studies (Daum et al., 2017; Duong et al., 2010; Talan et al., 2016) measured cure rate at 7-14 days, (n = 1709). For the outcome of adverse
events, the OR = 0.89, 95% CI [0.59, 1.35], p = .59, indicated the intervention of TMP-SMX was no different to the comparator of placebo (see Figure 4 &
Table 2).
Certainty Of The Evidence For Adverse Events for Children and Adults. The certainty of the body of evidence was very. The body of evidence
was assessed to have no serious imprecision, but was assessed to have serious risk of bias, serious inconsistency, and serious indirectness. Risk of bias
was serious due to potential selection bias of (Talan et al., 2016). This study made up 86% of the final weight of the meta-analysis results.
Inconsistency was serious due to each study measuring adverse events differently and moderate heterogeneity based on I 2 of 77%. Indirectness was
judged to be serious due to the inclusion of both adults and children (Talan et al. (2016).

* These guidelines do not establish a standard of care to be followed in every case. It is recognized that each case is different, and those individuals involved
in providing health care are expected to use their judgment in determining what is in the best interests of the patient based on the circumstances existing at
the time. It is impossible to anticipate all possible situations that may exist and to prepare guidelines for each. Accordingly, these guidelines should guide care
with the understanding that departures from them may be required at times.
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Cure Rate 7-10 days for Children, Clindamycin versus Placebo
One study (Daum et al., 2017) measured cure rate at 7-10 days, (n = 190). For the outcome of cure rate at 7—10 days, the OR = 1.97, 95% CI [1.04,
3.73], p = .04, indicated the intervention of clindamycin was favorable to the comparator of placebo (see Figure 6 & Table 3). The use of clindamycin would
result in a cure rate of 106 to 261 more patients per 1000.
Certainty Of The Evidence For Cure Rate at 7-10 days for Children. The certainty of the body of evidence was low. The body of evidence was
assessed to not have serious risk of bias, nor serious inconsistency, or serious indirectness, but very serious imprecision. Imprecision was very serious
due to the low number of events and participants (n = 190).
Adverse Events for Children, Clindamycin versus Placebo
One study (Daum et al., 2017) measured adverse events, (n = 190). For the outcome of adverse events, the OR = 3.76, 95% CI [1.74, 8.11], p = .005,
indicated the intervention of clindamycin was not favorable to the placebo comparator (see Figure 7 & Table 3). The use of clindamycin would result in a 23
to 184 more adverse events per 1000 patients.
Certainty Of The Evidence For Cure Rate at 7-10 days for Children. The certainty of the body of evidence was. The body of evidence was
assessed to not have serious risk of bias, nor serious inconsistency, or serious indirectness, but had very serious imprecision. Imprecision was very
serious due low number of events and participants (n = 190).
Recurrence at 1 year for Children, Antibiotics versus No-antibiotics
One study (Hogan et al., 2018) measured recurrence at 1 year, (n = 383). For the outcome of recurrence at 1 year, the OR = 0.37, 95% CI [0.17, 0.84], p
= .02, indicated the intervention of antibiotics (clindamycin, TMP-SMX, vancomycin) was favorable to the comparator of no-antibiotics (see Figure 8 & Table
4).
Certainty Of The Evidence For Recurrence at 1 year for Children.
The certainty of the body of evidence was low. The body of evidence was assessed to have no serious inconsistency and no serious indirectness, but
was assessed to have serious imprecision and serious risk of bias. Risk of bias was serious due to the low number of participants in the comparison
group. Imprecision was serious due to the low number of events (n = 90).
Identification of Studies
Search Strategy and Results (see Figure 1)
("skin and soft-tissue infection*" OR "skin and soft tissue infection*" OR SSTI OR SSTIs OR "Soft Tissue Infections"[Mesh] OR "Skin Diseases,
Infectious"[Mesh] OR "skin abscess*"[tiab] OR "skin lesion*"[tiab] OR "Subcutaneous abscess*"[tiab]) AND ("Drainage"[Mesh] OR "Incision and drainage"
OR "I&D" OR "incision & drainage") AND ("Treatment Outcome"[MeSH] OR "Follow-Up Studies"[Mesh] OR follow-up OR "Watchful Waiting"[Mesh] OR "AntiBacterial Agents"[Mesh] OR "Recurrence"[Mesh] OR antibiotic*[tiab] OR outcome*[tiab]) AND (child OR children OR pediatr* OR paediatr* OR infant OR
adolescence)
Records identified through database searching n = 147
Additional records identified through other sources n = 1
Studies Included in this Review
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in providing health care are expected to use their judgment in determining what is in the best interests of the patient based on the circumstances existing at
the time. It is impossible to anticipate all possible situations that may exist and to prepare guidelines for each. Accordingly, these guidelines should guide care
with the understanding that departures from them may be required at times.

Date Finalized: 4/06/2022

Citation
Daum et al. (2017)
Duong et al. (2010)
Hogan et al. (2018)
Talan et al. (2016)

Study Type
RCT
RCT
Cohort
RCT

Studies Not Included in this Review with Exclusion Rationale
Citation
Reason for exclusion
Gottlieb et al. (2019)
Pediatric study in the systematic review already included
Fahimi et al. (2015)
Pediatric study in the systematic review already included
Methods Used for Appraisal and Synthesis
a
The GRADEpro Guideline Development Tool (GDT) is the tool used to create the Summary of Findings (SOF) table(s) for this analysis. Using the GDT, the author of
this CAT rates the certainty of the evidence based on four factors: within-study risk of bias, consistency among studies, directness of evidence, and
precision of effect estimates. Each factor is subjectively judged against the author’s confidence of the estimated treatment effect. Confidence is
assessed as not serious, serious or very serious. If the attribute of serious or very serious is assessed, the author will provide an explanation.
b
Rayyan is a web-based software used for the initial screening of titles and / or abstracts for this analysis (Ouzzani, Hammady, Fedorowicz & Elmagarmid,
2017).
c
Review Manager (Higgins & Green, 2011) is a Cochrane Collaborative computer program used to assess the study characteristics as well as the risk of bias
and create the forest plots found in this analysis.
d
The Appraisal of Guidelines Research and Evaluation II (AGREE II) is an international instrument used to assess the quality and reporting of clinical practice
guidelines for this analysis (Brouwers et al. 2010).
c
The Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) flow diagram depicts the process in which literature is searched,
screened, and eligibility criteria is applied (Moher, Liberati, Tetzlaff, & Altman, 2009).
GRADEpro GDT: GRADEpro Guideline Development Tool (2015). McMaster University, (developed by Evidence Prime, Inc.). [Software]. Available
from gradepro.org.
b
Ouzzani, M., Hammady, H., Fedorowicz, Z., & Elmagarmid, A. (2016). Rayyan-a web and mobile app for systematic reviews. Systematic Reviews, 5(1),
210. doi:10.1186/s13643-016-0384-4
c
Higgins, J. P. T., & Green, S. e. (2011). Cochrane Handbook for Systematic Reviews of Interventions [updated March 2011] (Version 5.1.0 ed.): The
Cochrane Collaboration, 2011.
d
Brouwers, M.C. et al. for the AGREE Next Steps Consortium. (2010) AGREE II: Advancing guideline development, reporting and evaluation in
healthcare. Canadian Medical Association Journal, 182, E839-842. Retrieved from https://www.agreetrust.org/wp-content/uploads/2017/12/AGREEII-Users-Manual-and-23-item-Instrument-2009-Update-2017.pdf
c
Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA
Statement. PLoS Med 6(7): e1000097. doi:10.1371/journal.pmed1000097 For more information, visit www.prisma-statement.org.
a

Question Originator
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SSTI CPG Team
Medical Librarian Responsible for the Search Strategy
K. Swaggart, MLIS, AHIP
EBP Team or EBP Scholar’s Responsible for Analyzing the Literature
J. Dusin, MS, RD, LD, CPHQ
EBP Team Member Responsible for Reviewing, Synthesizing, and Developing this Document
J. Dusin, MS, RD, LD, CPHQ
Acronyms Used in this Document
Acronym
Explanation
AGREE II
Appraisal of Guidelines Research and Evaluation II
CAT
Critically Appraised Topic
EBP
Evidence Based Practice
MRSA
Methicillin-resistant S. aureus
PRISMA
Preferred Reporting Items for Systematic Reviews and Meta-Analyses
SSTI
Skin and Soft Tissue Infection
TMP-SMX
Trimethoprim / Sulfamethoxazole
Statistical Acronyms Used in this Document
Statistical Acronym
Explanation
CI
Confidence Interval
HR
Hazard Ratio
I2
Heterogeneity test
M or 𝑋̅
Mean
Mdn
Median
n
Number of cases in a subsample
N
Total number in sample
OR
Odds Ratio
P or p
Probability of success in a binary trial
RCT
Randomized controlled trial
SD
Standard deviation
SR
Systematic Review
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Figure 1
Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMSA)c
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Figure 2
Risk of Bias Summary
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Summary of Findings Table(s)
Table 2

Summary of Findings Tablea: TMP-SMX compared to Placebo
Certainty assessment
Participant
s
Risk of
(studies)
bias
Follow-up

Summary of findings

Inconsistenc Indirectnes Imprecisio Publicatio
y
s
n
n bias

Overall
certaint
y of
evidenc
e

Study event
rates (%)
With
Placeb
o

With
TMPSMX

Anticipated
absolute effects

Relativ
e effect
Risk
Risk
(95%
with
differenc
CI)
Placeb
e with
o
TMP-SMX

Cure Rate 7-14 days Children and Adults
1576
(3 RCTs)

seriousa,

not serious

seriousc

not serious

none

⨁⨁◯◯
Low

587/78 652/79
OR
751 per 73 more
2
4
1.55
1,000 per 1,000
(75.1% (82.1% (1.21 to
(from 34
)
)
1.97)
more to
105 more)

not serious

seriousd

none

⨁⨁◯◯
Low

133/16 145/16
OR
806 per 85 more
5
4
1.97
1,000 per 1,000
(80.6% (88.4% (1.04 to
(from 6
)
)
3.73)
more to
133 more)

seriousc

not serious

none

⨁◯◯◯
Very low

102/83 98/872
OR
122 per 12 fewer
7
(11.2%
0.89
1,000 per 1,000
(12.2%
)
(0.59 to
(from 46
)
1.35)
fewer to
36 more)

b

Cure Rate 7-10 days Children
329
(2 RCTs)

seriousb

not serious

Adverse Events Adults and Children
1709
(3 RCTs)

seriousa,
b

seriouse

Adverse Events Children
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Certainty assessment
672
(2 RCTs)

seriousb

not serious

Summary of findings

not serious

seriousd

none

⨁⨁◯◯
Low

99/333 88/339
OR
297 per 61 fewer
(29.7% (26.0%
0.73
1,000 per 1,000
)
)
(0.47 to
(from 131
1.15)
fewer to
30 more)

not serious

seriousd

none

⨁⨁◯◯
Low

15/52
13/46
OR
288 per 6 fewer
(28.8% (28.3%
0.97
1,000 per 1,000
)
)
(0.40 to
(from 149
2.34)
fewer to
198 more)

Recurrence 3 months Children
98
(1 RCT)

seriousf

not serious

Explanations
a. Potential selection bias due to physicians ability to exclude patients at higher risk (Talan et al., 2016). Talan et al. (2016) study has 86%
weight in meta-analysis.
b. Duong et al. (2010) not recruit enough study participants to detect significance and the medication compliance of the subjects was only
66%.
c. One study (Talan et al., 2016) included both adults and children.
d. Low number of events and subjects.
e. Adverse events measured differently in each study.
f. Study did not reach power and only a medication compliance rate of 66% (Doung et al., 2010).
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Table 3

Summary of Findings Table: Clindamycin compared to Placebo
Certainty assessment

Participants
(studies)
Follow-up

Risk
of
bias

Summary of findings
Study event rates
(%)

Anticipated absolute
effects
Overall
Relative
Publication certainty
effect
Risk
Inconsistency Indirectness Imprecision
Risk
bias
of
(95%
With
With
difference
with
evidence Placebo Clindamycin
CI)
with
Placebo
Clindamycin

Cure Rate 7-10 days
190
(1 RCT)

not
serious

not serious

not serious

very seriousa

none

⨁⨁◯◯
Low

61/89
(68.5%)

90/101
(89.1%)

OR 3.76 685 per
(1.74 to
1,000
8.11)

206 more
per 1,000
(from 106
more to 261
more)

not serious

seriousb

very seriousa

none

⨁◯◯◯ 32/257
Very low (12.5%)

58/266
(21.8%)

OR 1.96 125 per
(1.22 to
1,000
3.14)

93 more
per 1,000
(from 23
more to 184
more)

Adverse Events
523
(1 RCT)

not
serious

Explanations

a. Low number of events and participants
b. Includes children and adults

* These guidelines do not establish a standard of care to be followed in every case. It is recognized that each case is different, and those individuals involved 17
in providing health care are expected to use their judgment in determining what is in the best interests of the patient based on the circumstances existing at
the time. It is impossible to anticipate all possible situations that may exist and to prepare guidelines for each. Accordingly, these guidelines should guide care
with the understanding that departures from them may be required at times.

Date Finalized: 4/06/2022

Table 4

Summary of Findings Table: Antibiotics compared to No-Antibiotics
Certainty assessment

Summary of findings
Study event rates
(%)

Anticipated absolute
effects

Overall
Relativ Risk with
Participant
certaint With Noe
NoRisk
s
Risk of Inconsisten Indirectnes Imprecisio Publicatio
Antibiotic
y of
effect Antibiotic difference
With
(studies)
bias
cy
s
n
n bias
s
evidenc
Antibioti (95%
s
with
Follow-up
(observat
e
CI)
cs
(observat Antibiotic
ional
ional
s
study)
study)
Recurrent SSTI at 1 year
383
serious
a
(1
observation
al study)

not serious

not
serious

seriousb

none

⨁◯◯◯
Very low

18/28
(64.3%)

143/355
(40.3%)

OR
0.37
(0.17
to
0.84)

643 per
1,000

243 fewer
per 1,000
(from 409
fewer to
41 fewer)

Explanations

a. Low number of participants in the comparison group
b. Low number of events
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Meta-analysis(es)
Figure 3

Comparison: TMP-SMX versus Placebo, Outcome: Cure Rate
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Figure 4

Comparison: TMP-SMX versus Placebo, Outcome: Adverse Events

* These guidelines do not establish a standard of care to be followed in every case. It is recognized that each case is different, and those individuals involved 20
in providing health care are expected to use their judgment in determining what is in the best interests of the patient based on the circumstances existing at
the time. It is impossible to anticipate all possible situations that may exist and to prepare guidelines for each. Accordingly, these guidelines should guide care
with the understanding that departures from them may be required at times.

Date Finalized: 4/06/2022

Figure 5

Comparison: TMP-SMX versus Placebo, Outcome: Recurrence at 3 months
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Figure 6

Comparison: Clindamycin versus Placebo, Outcome: Cure Rate 7 to 10 days
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Figure 7

Comparison: Clindamycin versus Placebo, Outcome: Adverse Events
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Figure 8

Comparison: Antibiotics versus No Antibiotics, Outcome: Recurrent SSTI at 1 Year
Antibiotics versus No-Antibiotics (observational study), outcome: 4.1 Recurrent SSTI at 1 year.

* These guidelines do not establish a standard of care to be followed in every case. It is recognized that each case is different, and those individuals involved 24
in providing health care are expected to use their judgment in determining what is in the best interests of the patient based on the circumstances existing at
the time. It is impossible to anticipate all possible situations that may exist and to prepare guidelines for each. Accordingly, these guidelines should guide care
with the understanding that departures from them may be required at times.

Date Finalized: 4/06/2022

Characteristics of Intervention Studies
Daum et al. (2017)
Methods

Randomized Control Trial

Participants

Participants: Outpatient adults and Children May 2009 through January 2015
Setting: Urgent care clinics, emergency departments, and affiliated clinics at six sites: the University of Chicago
Medical Center, Chicago; San Francisco General Hospital, San Francisco; Harbor–University of California,
Los Angeles, Medical Center, Torrance; Vanderbilt University Medical Center, Nashville, Washington University, St.
Louis and Morehouse School of Medicine Emory University, Atlanta
Randomized into study: N = 786
• Group 1, Clindamycin: n = 266
• Group 2, TMP-SMX: n = 263
• Group 3, Placebo: n = 257
Completed Study: N = 678
• Group 1: n = 234
• Group 2: n = 226
• Group 3: n = 218
Gender, males (as defined by researchers):
• Group 1: n = 140 (52.6%)
• Group 2: n = 152 (57.8%)
• Group 3: n = 156 (60.7%)
Race / ethnicity or nationality (as defined by researchers):
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Age

Inclusion Criteria:
• Single abscess (defined as a circumscribed, drainable collection of pus) with a greatest diameter of 5.0 cm or
less (≤3 cm for participants 6 to 11 months of age and ≤4 cm for participants 1 to 8 years of age),
• Evidenced by two or more of the following signs or symptoms for at least 24 hours:
o Erythema
o Swelling or induration
o Local warmth
o Purulent drainage
o Tenderness to pain or palpation
Exclusion Criteria:
• Superficial skin infections (e.g., impetigo)
• Infection at a body site requiring specialized management (e.g., perirectal, genital, or hand infection)
• Human or animal bite
• Oral temperature higher than 38.5°C (or >38.0°C for children 6 to 11 months of age)
• Presence of systemic inflammatory response syndrome criteria
• Immunosuppressive therapy or an immunocompromising condition (e.g., diabetes or chronic renal failure),
• Body-mass index (the weight in kilograms divided by the square of the height in meters) higher than 40
• Surgical site or prosthetic device infection
• Systemic anti-staphylococcal antibacterial therapy in the previous 14 days
• Required hospitalization
• Lived in a long-term care facility
• cancer
• Inflammatory disorder treated
Power Analysis: The trial was designed as a superiority trial with 80% power to detect a 10-percentage-point
absolute
difference in cure rates (e.g., 85% vs. 95%), 786 participants were required (262 per group).
Interventions

Both: After incision and drainage of the abscess and determination of the size of the abscess, participants were
randomly assigned in a 1:1:1 ratio to receive placebo, clindamycin, or TMP-SMX. Participants were seen at the end of
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treatment (day 12), at the test-of-cure visit (7 to 10 days after the prescribed 10-day course of therapy), and at the
1-month follow-up (day 40).
• Group 1: Clindamycin was given as two 150-mg tablets three times daily
• Group 2: TMP-SMX was given as two tablets (containing 80mg of trimethoprim and 400 mg of
sulfamethoxazole) twice daily plus one dose of placebo pills
• Group 3: Two placebo pills given three times daily
Outcomes

Primary outcome(s):
• Clinical cure by day 7 to 10 days*
Secondary outcome(s)
• Clinical cure at day 40*
Safety outcome(s):
• Adverse events*
*Outcomes of interest to the CMH CPG or CAT development team

Notes

• Ten days after therapy in the intention-to-treat population, the cure rate:
o Clindamycin: 221 of 266 participants [83.1%]
o TMP-SMX: 215 of 263 participants [81.7%]
o Placebo: 177 of 257 participants [68.9%], p < .001 for both comparisons
• New infections at 1 month of follow-up
o Clindamycin: 15 of 221, 6.8%
o TMP-SMX: 29 of 215, 13.5%, p = .03
o Placebo: 22 of 177, 12.4%, p = .06
• Adverse events
o Clindamycin: 58 of 265, 21.9%
o TMP-SMX: 29 of 261, 11.1%
o Placebo 32 of 255, 12.5%

Risk of bias
Bias

Judgment

Random sequence
generation (selection bias)

Low risk

Allocation concealment
(selection bias)

Low risk

Blinding of participants and
personnel (performance
bias)

Low risk

Support for judgment
Variable-block randomization
Allocation determines by independent statistics and data-coordinating center
Participants and all study staff were unaware of the study-group assignments
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Blinding of outcome
Unclear risk
Staff assessing outcomes were unaware of study groups
assessment (detection bias)
Incomplete outcome data
(attrition bias)

Low risk

Selective reporting
(reporting bias)

Low risk

Other bias

Low risk

Intention-to-Treat was used for primary outcome
All outcomes reported
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Duong et al. (2010)
Methods

Randomized Control Trial

Participants

Participants: Pediatric Patients July 2006 through February 2008
Setting: Emergency Department in Saint Louis Medical Center
Randomized into study: N = 161
• Group 1, TMP-SMX: n = 77
• Group 2, Placebo: n = 85
Completed Study: N = 149
• Group 1: n = 73
• Group 2: n = 76
Gender, males (as defined by researchers):
• Group 1: n = 28 (39%)
• Group 2: n = 34 (45%)
Race / ethnicity or nationality (as defined by researchers):
• Black: 128/149 (85%)
Age, (<5 years)
• Group 1: 40/76 (53%)
• Group 2: 39/73 (53%)
Inclusion Criteria:
• Diagnostic criteria for skin abscess included the presence of all of the following features:
o Acute onset within 1 week
o Fluctuance,
o Erythema
o Induration
o Tenderness, with or without purulent drainage.
Exclusion Criteria:
• Chronic health problems
• Immunosuppressive medications
• Current antibiotic usage
• Contraindication to TMP-SMX
• Minor or superficial skin infections
Power Analysis: The sample size of 81 per group was calculated according to assumed treatment
failure rate of 3.3% with antibiotics, an equivalence threshold of 7% (allowing up to 10.3% failure rate
with placebo), to achieve a power of 0.80 (0.05).
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Interventions

Both:

•

Ultrasonography was available, measurements were made in 2 dimensions, diameter and depth.
Local anesthetic or procedural sedation was used at the discretion of the attending physician
• The skin overlying all skin abscesses was cleansed with 10% povidone iodine solution and then
incised with a no. 11 blade, probed for loculations, and irrigated with normal saline solution.
• Abscess cultures obtained immediately after surgical incision and sent for culture and antibiotic
sensitivity testing.
▪ Group 1: TMP-SMX dose for mild bacterial infections (10-12 mg trimethoprim/kg/ day divided
into 2 doses, with a maximum dose of 160 mg trimethoprim/dose).
▪ Group 2: The placebo consisted of a Maalox and tonic water combination that resembled the
antibiotic in color, texture, and taste.
Outcomes

Primary outcome(s):
• Clinical resolution or failure at 10 days*
Secondary outcome(s)
• New Lesions on day 10
• New lesions on day 3-months
Safety outcome(s):
• Adverse events*
*Outcomes of interest to the CMH CPG or CAT development team

Notes

•
•
•

The failure rates were 5.3% (n = 4/76) and 4.1% (n = 3/73) in the placebo and antibiotic groups,
respectively, yielding a difference of 1.2.
New lesions occurred at the 10-day follow-up: 19 on placebo (26.4%) and 9 on antibiotics (12.9%),
yielding a difference of 13.5.
At the 3-month follow-up, 15 of 52 (28.8%) in the placebo group and 13 of 46 (28.3%) in the
antibiotic group developed new lesions. The difference was 0.5%.

Risk of bias
Bias

Judgment

Random sequence
generation (selection bias)

Low risk

Allocation concealment
(selection bias)

Unclear risk

Blinding of participants and Low risk
personnel (performance
bias)

Support for judgment
Computer randomization program
Not discussed
Participants and personal blinded
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Blinding of outcome
assessment (detection
bias)

Low risk

Incomplete outcome data
(attrition bias)

High risk

Selective reporting
(reporting bias)

Low risk

Other bias

High risk

The patient, parents, and clinician who assessed the clinical outcome
were blinded to group assignment
Per-protocol and study did not meet power
All outcomes reported
Low compliance rate of medications of 66%
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Hogan et al. (2018)
Methods

Cohort, prospectively

Participants

Participants: <21-year-old, 2008-2016
Setting: ED or outpatient setting, St Louis, Missouri and Springfield, Illinois
Number enrolled into study: N = 357
• Group 1, Antibiotics: n = 331
• Group 2, No Antibiotics: n = 26
Gender, males (as defined by researchers):
• n = 167 (40%)
Race / ethnicity or nationality (as defined by researchers):
• White n = 143 (37%)
• African American or biracial n = 237 (62%)
• Asian n = 2 (1%)
Inclusion Criteria:
• <21 years old with community-onset S. aureus SSTI and S. aureus colonization
• Presented with acute, community-onset SSTI for which an Incision and drainage procedure was
performed
Exclusion Criteria:
• Immunodeficiency
• Hospitalized within the previous 14 days
• Decolonization measures (with mupirocin ointment, chlorhexidine gluconate, or bleach baths) in the
prior month
Covariates Identified:
• Age
• Race
• Methicillin susceptibility of the SSTI isolate (MRSA vs methicillin-susceptible S. aureus)
• Prescription of decolonization measures for baseline SSTI
• Burden (i.e., number of anatomical sites) of S. aureus colonization at baseline

Interventions

Both: Incision and Drainage
• Group 1: Received guideline-recommended empiric systemic antibiotics
o Clindamycin, n = 220 (57%)
o TMP-SMX, n = 199 (52%)
o Vancomycin n = 19 (5%)
o β-lactam n = 12 (3%)
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• Group 2: Did not receive guideline-recommended empiric systemic antibiotics
Outcomes

Primary outcome(s):
• Colonized with S. aureus at follow-up
Secondary outcome(s):
• Recurrent SSTI at 1 year

Notes

Results:
• Antibiotics for purulent SSTI were less likely to remain colonized at follow-up sampling, adjusted hazard
ratio (aHR) = 0.49; 95% CI [.30, .79]
• Antibiotics are less likely to have recurrent SSTI, aHR = 0.57, 95% CI [.34, .94]
• Clindamycin was more effective than TMP-SMX in eradicating S. aureus colonization (44% vs 57%
remained colonized, p = .03) and preventing recurrent SSTI (31% vs 47% experienced
recurrence, p = .008).
Limitations:
• Limited number of antibiotic free patients
• Only looked at patients with S. aureus
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Talan et al. (2016)
Methods

Randomized Control Trial

Participants

Participants: Adults and children older than 12 years of age, April 2009 to April 2013
Setting: Five US Emergency Departments
Randomized into study: N = 1265
• Group 1, TMP-SMX: n = 636
• Group 2, Placebo: n = 629
Completed Study: N = 1013
• Group 1: n = 504
• Group 2: n = 509
Gender, males (as defined by researchers):
• Group 1: n = 364 (57.8%)
• Group 2: n = 362 (58.7%)
Race / ethnicity or nationality (as defined by researchers):
• Not reported
Age, Median (IQR)
• Group 1: 35 (26-47)
• Group 2: 35 (26-48)
Inclusion Criteria:
• Older than 12 years of age
• Cutaneous lesion that was suspected to be an abscess on the basis of physical examination and
ultrasonography or examination alone
• Purulent material on surgical exploration
• Lesion present for less than 1 week
• At least 2.0 cm in diameter
• Intended outpatient treatment.
• Agreed to return for reevaluation
Exclusion Criteria:
• Indwelling device; suspected osteomyelitis or septic arthritis; diabetic foot, decubitus, or ischemic
ulcer; mammalian bite; wound with organic foreign body; infection of another organ system/site;
perirectal, perineal or paronychial location; intravenous drug use within previous month and fever;
underlying skin condition; long-term care residence; incarceration; immunodeficiency; creatinine
clearance <50 mL/min; cardiac condition with risk of endocarditis; allergy or intolerance to
trimethoprim-sulfamethoxazole; taking warfarin, phenytoin, or methotrexate; known G-6-PD or folic
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acid deficiency; pregnant or lactating; trimethoprim-sulfamethoxazole treatment within 24 hours;
concurrent treatment with topical or systemic antibiotic; or enrolled in the study within 12 weeks.
Power Analysis:
Enrollment of 590 participants would provide a power of 90% to detect an absolute between-group
difference of 7.5 percentage points, assuming a cure rate of 90%
Interventions

Both: Incision and drainage of abscess
• Group 1: 7-day course of trimethoprim–sulfamethoxazole (four single-strength pills, each containing
80 mg of trimethoprim and 400 mg of sulfamethoxazole, twice daily)
• Group 2: Placebo (four pills containing microcrystalline cellulose, twice daily).

Outcomes

Primary outcome(s):
• Clinical cure of abscess, assessed 7 to 14 days
Secondary outcome(s)
• Subsequent surgical drainage procedures
• Skin infections at new sites
Safety outcome(s):
• Adverse events
*Outcomes of interest to the CMH CPG or CAT development team

Notes
Risk of bias table
Bias

Judgment

Random sequence
generation (selection bias)

Low risk

Allocation concealment
(selection bias)

Low risk

Support for judgment
Web-based randomization, assigned participants in a 1:1 ratio
Drug package identical

Blinding of participants and Low risk
personnel (performance
bias)

Participants and personnel blinded

Blinding of outcome
Low risk
assessment (detection bias)

Outcome assessors blinded

Incomplete outcome data
(attrition bias)

Intention-to-treat, secondary outcome per-protocol

Low risk
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Selective reporting
(reporting bias)

Low risk

Other bias

Unclear risk

All outcomes reported
potential selection bias due to physicians’ ability to exclude patients at higher risk.
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Appendix A
ASSESSMENT
Problem
Is the problem a priority?
JUDGEMENT
○
○
○
●
○
○

No
Probably no
Probably yes
Yes
Varies
Don't know

RESEARCH EVIDENCE

ADDITIONAL CONSIDERATIONS

Skin and soft tissue infection is a common presentation
in pediatric emergency departments and ambulatory
settings, of which almost half are abscesses (Gottlieb &
Peksa, 2018; Taira et al., 2009). Standard clinical
treatment for abscesses includes incision and drainage,
but the utility of antibiotics for simple abscesses remains
unclear (Singer & Talan, 2014). The Infectious Diseases
Society of America recommends that incision and
drainage are likely adequate for simple abscesses
(Stevens et al., 2014).

Desirable Effects
How substantial are the desirable anticipated effects?
JUDGEMENT
○
○
●
○
○
○

Trivial
Small
Moderate
Large
Varies
Don't know

RESEARCH EVIDENCE

ADDITIONAL CONSIDERATIONS

Desirable effects of giving antibiotics
• Clinical Cure
• Decreased recurrence
• Improvement in pain

Undesirable Effects
How substantial are the undesirable anticipated effects?
JUDGEMENT

RESEARCH EVIDENCE

ADDITIONAL CONSIDERATIONS
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○
○
○
○
●
○

Large
Moderate
Small
Trivial
Varies
Don't know

Undesirable effects of giving antibiotics
• Adverse Events
• Increase in bacterial resistance
Varies by antibiotic type

TMP-SMX and clindamycin have different side
effect, but the risk of Steven Johnson
Syndrome or Toxic Epidermal Necrolysis are
the potential adverse events of greatest
concern with TMP-SMX.
Additionally, the poor palatability of
clindamycin may negatively impact medication
compliance.

Certainty of evidence
What is the overall certainty of the evidence of effects?
JUDGEMENT
○
●
○
○
○

Very low
Low
Moderate
High
No included studies

RESEARCH EVIDENCE

ADDITIONAL CONSIDERATIONS

Certainty of evidence for TMP-MPX and clindamycin
following incision and drainage on clinical cure and
three-month recurrence is low

Values
Is there important uncertainty about or variability in how much people value the main outcomes?
JUDGEMENT

RESEARCH EVIDENCE

○ Important uncertainty or
variability
○ Possibly important uncertainty
or variability
● Probably no important
uncertainty or variability
○ No important uncertainty or
variability

Probably no important uncertainty or variability in how
much people value the main outcome

ADDITIONAL CONSIDERATIONS

Balance of effects
Does the balance between desirable and undesirable effects favor the intervention or the comparison?
JUDGEMENT

RESEARCH EVIDENCE

ADDITIONAL CONSIDERATIONS
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○ Favors the comparison
Clinical cure versus all undesirable effects (adverse
○ Probably favors the comparison events)
○ Does not favor either the
• Probably favors the intervention of antibiotics
intervention or the comparison
● Probably favors the
intervention
○ Favors the intervention
○ Varies
○ Don't know
Resources required
How large are the resource requirements (costs)?
JUDGEMENT
○
○
●
○
○
○
○

Large costs
Moderate costs
Negligible costs and savings
Moderate savings
Large savings
Varies
Don't know

RESEARCH EVIDENCE

ADDITIONAL CONSIDERATIONS

Cost is negligible

There is cost associated with antibiotics, but
there are generic, inexpensive formulations of
both TMP-SMX and clindamycin.
According to the CM standard charges for
2022, self-pay costs per unit include:
Clindamycin 150mg capsule – $7.07
Clindamycin 300mg capsule - $10.13
Clindamycin 75mg/5ml liquid - $2.55
TMP 40mg, SMX 200mg/5ml liquid - $2.64
TMP 80mg, SMX 400mg tablet - $$7.79

Certainty of evidence of required resources
What is the certainty of the evidence of resource requirements (costs)?
JUDGEMENT
○
○
○
●
○

Very low
Low
Moderate
High
No included studies

RESEARCH EVIDENCE

ADDITIONAL CONSIDERATIONS

There is certainty in the required resources

Cost effectiveness
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Does the cost-effectiveness of the intervention favor the intervention or the comparison?
JUDGEMENT

RESEARCH EVIDENCE

○ Favors the comparison
Cost favors the intervention
○ Probably favors the comparison
○ Does not favor either the
intervention or the comparison
○ Probably favors the
intervention
● Favors the intervention
○ Varies
○ No included studies

ADDITIONAL CONSIDERATIONS
While cost is associated with the antibiotic
prescription, it is negligible compared to the
cost of treatment failure (repeat clinic or ED
visit, readmission, and/or repeat incision and
drainage).

Equity
What would be the impact on health equity?
JUDGEMENT
○
○
○
○
○
●
○

Reduced
Probably reduced
Probably no impact
Probably increased
Increased
Varies
Don't know

RESEARCH EVIDENCE

ADDITIONAL CONSIDERATIONS

The cost of medication without insurance could impact
subgroup populations. Subgroups may have less reliable
transportation to a pharmacy. Subgroups may also have
language or literacy barriers that impact the efficacy of
prescription instructions.

Please see standard costs above.

Acceptability
Is the intervention acceptable to key stakeholders?
JUDGEMENT
○
○
●
○
○
○

No
Probably no
Probably yes
Yes
Varies
Don't know

RESEARCH EVIDENCE

ADDITIONAL CONSIDERATIONS

Families and clinicians are likely to accept the
intervention.

Feasibility
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Is the intervention feasible to implement?
JUDGEMENT
○
○
○
●
○
○

RESEARCH EVIDENCE

No
Probably no
Probably yes
Yes
Varies
Don't know

ADDITIONAL CONSIDERATIONS

The intervention is feasible

SUMMARY OF JUDGEMENTS
JUDGEMENT
PROBLEM

No

Probably no

Probably yes

Yes

Varies

Don't know

DESIRABLE
EFFECTS

Trivial

Small

Moderate

Large

Varies

Don't know

UNDESIRABLE
EFFECTS

Large

Moderate

Small

Trivial

Varies

Don't know

CERTAINTY OF
EVIDENCE

Very low

Low

Moderate

High

VALUES

Important
uncertainty or
variability

Possibly
important
uncertainty or
variability

Probably no
important
uncertainty or
variability

No important
uncertainty or
variability

BALANCE OF
EFFECTS

Favors the
comparison

Probably
favors the
comparison

Does not favor
either the
intervention or
the comparison

Probably
favors the
intervention

No included
studies

Favors the
intervention

Varies

Don't know
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JUDGEMENT
RESOURCES
REQUIRED

Large costs

Moderate costs

Negligible
costs and
savings

Moderate
savings

CERTAINTY OF
EVIDENCE OF
REQUIRED
RESOURCES

Very low

Low

Moderate

High

COST
EFFECTIVENESS

Favors the
comparison

Probably
favors the
comparison

Does not favor
either the
intervention or
the comparison

Probably favors
the intervention

Favors the
intervention

Varies

No included
studies

EQUITY

Reduced

Probably
reduced

Probably no
impact

Probably
increased

Increased

Varies

Don't know

ACCEPTABILITY

No

Probably no

Probably yes

Yes

Varies

Don't know

FEASIBILITY

No

Probably no

Probably yes

Yes

Varies

Don't know

Large savings

Varies

Don't know

No included
studies

TYPE OF RECOMMENDATION
Strong recommendation
against the intervention

Conditional
recommendation against
the intervention

○

○

Conditional
Conditional
Strong recommendation for
recommendation for either recommendation for the
the intervention
the intervention or the
intervention
comparison
○
○
●

CONCLUSIONS
Recommendation
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A conditional recommendation is made for the use of antibiotics for abscesses, based on the GRADE Evidence to Decision instrument the
Summary of Findings Table. The overall certainty in the evidence is low to very low. In pediatric patients, the use of antibiotics following
incision and drainage was favorable for cure rate versus placebo. There is little evidence for or against antibiotics following incision and
drainage for abscesses <2cm. (see Summary by Outcome for substantiation of recommendations).
The SSTI CPG Subcommittee discussed additional considerations using the GRADE Evidence to Decision instrument a found in the appendix
to recommend antibiotic therapy for abscess following incision and drainage at Children’s Mercy based on feasibility, value, and compliance
for all stakeholders.
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Appendix B
Order Set (Inpatient)
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Order Set (ED and Outpatient)
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